Elizabeth A. Mittendorf, MD, PhD, a breast cancer surgeon and international leader in breast cancer vaccines, recently joined Brigham and Women’s Hospital (BWH) from the MD Anderson Cancer Center in Houston, where her research focused on vaccines that target the HER2 protein expressed on many breast tumors. At the Brigham, her work focuses on advancing our understanding of breast cancer immunotherapies.Read More
A drug whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), has become a standard first-line therapy for certain newly diagnosed patients with advanced kidney cancer. Additionally, several combination therapies are being used or tested at DF/BWCC and elsewhere against this aggressive cancer.
Over a decade ago, Christopher Crum, MD, of Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), helped design the protocol that revealed the fallopian tubes to be the origin of most high-grade serous carcinomas (HGSCs), the tumor type afflicting over two-thirds of women with ovarian cancer.
The Center for Oncoendocrinology at Brigham and Women’s Hospital was established to provide expert endocrine care for cancer patients during and after treatment. Endocrinologists at the Center, a program of Dana-Farber/Brigham and Women’s Cancer Center, can provide specialized knowledge of endocrine issues that may affect your cancer patient.
Specialists from Dana-Farber/Brigham and Women’s Cancer Center, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital recently introduced the Breast Cancer Personalized Risk Assessment, Education and Prevention (B-PREP) Program for patients at increased risk for breast cancer and for patients who want to better understand their risk. Read More
Dana-Farber/Brigham and Women’s Cancer is one of few centers in the country certified to offer this new approach.
Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women’s Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration (FDA) on Oct.19. Dana-Farber/Brigham and Women’s Cancer Center was the only facility in the northeast to be part of the clinical trial that led to FDA approval and is one of a few locations certified to offer this new therapy nationwide. Read More